logo-loader
viewGlaxoSmithKline PLC

GlaxoSmithKline posts positive interim study on HIV prevention drug

Injectable cabotegravir is 69% more effective than daily tablets of emtricitabine/tenofovir disoproxil fumarate, the current standard of care

GlaxoSmithKline PLC - GlaxoSmithKline posts positive interim analysis on HIV prevention drug

GlaxoSmithKline PLC (LON:GSK) announced its HIV prevention drug cabotegravir is more effective than the current standard of care according to interim analysis.

ViiV Healthcare, Glaxo’s specialist HIV drugs division developed with fellow giants Pfizer and Shionogi, enrolled 4,600 participants in North and South America, Asia, and Africa to compare cabotegravir with daily tablets of emtricitabine/tenofovir disoproxil fumarate.

READ: GlaxoSmithKline to offload entire holding in Hindustan Unilever

Glaxo’s treatment, which is an injection to be administered every two months, was found to be 69% more effective in preventing HIV acquisition in men who have sex with men (MSM) and transgender women who have sex with men.

“We are thrilled with the results not only because of the high efficacy of cabotegravir but also because we have demonstrated high efficacy in a study that adequately represents some of the populations most disproportionately impacted by HIV -- black MSM in the US, young MSM globally and transgender women,” said Kimberly Smith, head of research & development at ViiV Healthcare.

Shares rose 1% to 1,666p on Monday morning.

--Adds shares--

Quick facts: GlaxoSmithKline PLC

Price: 1575 GBX

LSE:GSK
Market: LSE
Market Cap: £79.02 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

1 day ago

2 min read